User menu

A phase II study of raltitrexed ('Tomudex') as second or third line treatment for patients (pts) with advanced soft tissue sarcomas (ASTS) refractory to doxorubicin containing regimens

Bibliographic reference Blay, J. -Y. ; Judson, I ; Rodenhuis, S ; Hermans, Cédric ; Smith, M. ; et. al. A phase II study of raltitrexed ('Tomudex') as second or third line treatment for patients (pts) with advanced soft tissue sarcomas (ASTS) refractory to doxorubicin containing regimens.In: Annals of Oncology, Vol. 9, p. 118-118 (1998)
Permanent URL http://hdl.handle.net/2078.1/62398